| [1] |
Tumor Gene Diagnosis Committee of the China Anti⁃Cancer Association, Integrative Oncology Branch of the China Anti⁃Cancer Association.
Chinese expert consensus on the localization of bioinformatics analysis for tumor genetic diagnosis using next⁃generation sequencing (2024 edition)
[J]. Chinese Journal of Oncology Prevention and Treatment, 2024, 16(6): 638-649.
|
| [2] |
Tumor marker committee of Chinese anti-cancer association.
Expert consensus on clinical practice of ctDNA next generation sequencing (2022 edition)
[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(3): 240-252.
|
| [3] |
ZHANG Huanqin, LIU Yang, GUO Xu, XING Jinliang, QUAN Zhibo.
Challenges and countermeasures of detecting ultra-low frequency mutations in tumors based on next-generation sequencing
[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(5): 553-558.
|
| [4] |
Genetic Tumor Markers Collaboration Group, Tumor Biomarker Committee, China Anti⁃cancer Association, .
Expert consensus on clinical detection and application of homologous recombination deficiency, 2021
[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(4): 329-338.
|
| [5] |
Genetic Tumor Markers Collaboration Group, Tumor Biomarker Committee, China Anti-cancer Association, Molecular Pathology Collaboration Group, Tumor Pathology Committee, China Anti-Cancer Association.
Chinese expert consensus on tumor mutational burden testing and clinical application
[J]. Chinese Journal of Oncology Prevention and Treatment, 2020, 12(5): 485-494.
|
| [6] |
FU Xiao, YAO Yu .
Research progress of clinical application of circulating tumor cells
[J]. Chinese Journal of Oncology Prevention and Treatment, 2020, 12(3): 244-249.
|
